About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
A Comparison of Daily Average Consumption of Oxycodone Controlled Release (OxyContin CR) and Oxymorphone Extended Release (Opana ER) in Patients With Low Back Pain
In a retrospective study, patients needed one more oxycodone CR tablet per day compared with oxymorphone ER tablets to relieve pain. The authors suggest that switching patients from the highest oxycodone CR strength to the equivalent highest oxymorphone ER strength could generate significant savings in wholesale acquisition costs.
Todd Berner, MD; Heather Thomson, MBA, MS; Ann Hartry, PhD; R. Amy Puenpatom, PhD; Rami Ben-Joseph, PhD; and Sheryl L. Szeinbach, PhD, MS, BS Pharm
Opinion & Analysis
Past and Present Challenges for the FDA
Over the years, the FDA has been given many new tasks without the resources to carry them out. The author opines that concentrating solely on regulating drugs and medical devices, simplifying funding procedures, and eliminating user fees could go a long way in strengthening the agency.
Among the topics addressed were the contradictory effects of zoledronic acid (Zometa), a study on dual blockade of HER-2 with lapatinib (Tykerb) and trastuzumab (Herceptin), and a trial of combined everolimus (Afinitor) and tamoxifen (Nolvadex).
Stroke now accounts for one in 18 deaths in the U.S. Managing hypertensive crisis in acute ischemic stroke with thrombolytic agents while avoiding bleeding events, educating patients on signs and symptoms, and assessing patients’ neurological scores are some of the challenges inherent in delivering optimal care.
Edward H. Lee, PharmD
Topics include vilazodone (Viibryd) for major depressive disorder; spinosad topical suspension 0.9% (Natroba) in head lice infestation; and ioflupane iodine-123 injection (DaTscan), an imaging agent used for evaluating parkinsonian syndromes.
Marvin M. Goldenberg, PhD, RPh, MS
Dr. Nash discusses the implications of the Patient Safety Act for P&T committee members.
David B. Nash, MD, MBA
Decreasing the potential for mistakes with investigational drugs
Matthew Grissinger, RPh, FASCP
Hospital Payments Will Depend on Performance in Fiscal Year 2013
Medicare will soon announce rules of the road for value-based purchasing payments.
FDA approvals, drug indications, and updates
Telavancin (Vibativ) for the treatment of gram-positive infections
Polina Plotkin, PharmD; Khusbu Patel, PharmD; Amy Uminski, PharmD; and Nino Marzella, BS, MS, PharmD